University of Pennsylvania
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Pennsylvania sits in the top decile of US sponsors by registered trial count (#15 of 15,751 sponsors by registered trial count).
University of Pennsylvania: 1,423 sponsored US clinical trials, 199 recruiting.
University of Pennsylvania sponsors 1,423 registered US clinical trials on ClinicalTrials.gov, 199 of them currently recruiting, and 982 completed. 130 of these trials are in Phase 3-4 (later-stage) and 339 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 17 trials.
Top-decile sponsor footprint
University of Pennsylvania ranks in the top decile of sponsors by registered trial count (#15 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
1,423 total, page 29 of 29
Relapse Prevention for Bipolar Type-II Disorder
NCT00044616
Cognitive Behavioral Treatment of Pediatric Trichotillomania
NCT00043563
Treatment for Alcoholism and Post-Traumatic Stress Disorder (Naltrexone)
NCT00006489
Tamoxifen-MRI Study
NCT00295100
Ectopic Pregnancy Biomarkers
NCT00194168
Sertraline for Alcohol Dependence and Depression
NCT00004554
Bio-Behavioral Predictors of the Efficacy of Nicotine Replacement Therapy (NRT)
NCT00326781
Risk Factors of Ectopic Pregnancy
NCT00194207
Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1
NCT00142844
Effectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2
NCT00158132
Brain Imaging Study in Menopausal Women With and Without Major Depressive Disorder
NCT00626340
Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence - 1
NCT00218660
The Role of GABA and Neurosteroids in Premenstrual Dysphoric Disorder
NCT00678574
Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence
NCT00167232
Treatment of Obsessive-Compulsive Disorder (OCD) in Children
NCT00000384
Piracetam for Treatment of Cocaine Addiction - 3
NCT00000198
Selegiline in Treatment of Cocaine Dependence - 2
NCT00000188
Ritanserin in Treatment of Cocaine Dependence - 1
NCT00000187
Carbamazepine Treatment for Cocaine Dependence - 5
NCT00000191
Cocaine in Parotid Saliva, Blood and Urine - 4
NCT00000190
Gepirone vs Placebo in Treatment of Cocaine Dependence - 3
NCT00000189
High School Football and Adult Health
NCT03914573
Effectiveness and Costs of Enhanced Cocaine Treatments
NCT00167258
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 182 |
| Phase 2 | 157 |
| Phase 3 | 43 |
| Phase 4 | 87 |
Therapeutic Areas
What is open in the University of Pennsylvania pipeline
199 recruiting of 1,423 indexed (14% open); 982 completed (69%).
Phase mix: 130 late (III/IV) vs 339 early (I/II) (early-phase heavy).
Top condition: Obesity (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.